Generation of four severe early-onset chronic obstructive pulmonary disease (COPD) patient-derived induced pluripotent stem cell lines from peripheral blood mononuclear cells.


Journal

Stem cell research
ISSN: 1876-7753
Titre abrégé: Stem Cell Res
Pays: England
ID NLM: 101316957

Informations de publication

Date de publication:
10 2021
Historique:
received: 06 05 2021
revised: 06 09 2021
accepted: 19 09 2021
pubmed: 9 10 2021
medline: 26 11 2021
entrez: 8 10 2021
Statut: ppublish

Résumé

Evidence highlights the concept of multiple trajectories leading to COPD. Early-life events (i.e., in utero lung development) may influence the maximally attained lung function and increase the risk to develop COPD. Human pluripotent stem cells (hiPSC) represent a unique opportunity to model lung development. We generated hiPSC lines from four highly characterized COPD patients with early onset and severe phenotype. Peripheral blood mononuclear cells (PBMCs) were reprogrammed using integration-free Sendai Virus. The cell lines had normal karyotype, expressed pluripotency hallmarks, and differentiated into the three primary germ layers. These lines offer a tool to study early-life origins of COPD.

Identifiants

pubmed: 34624616
pii: S1873-5061(21)00397-4
doi: 10.1016/j.scr.2021.102550
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102550

Informations de copyright

Copyright © 2021 CHU de Montpellier. Published by Elsevier B.V. All rights reserved.

Auteurs

Engi Ahmed (E)

IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier 34000, France; Department of Respiratory Diseases, CHU Montpellier, Arnaud de Villeneuve Hospital, INSERM, Montpellier 34000, France.

Mathieu Fieldes (M)

IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier 34000, France.

Joffrey Mianné (J)

IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier 34000, France.

Chloé Bourguignon (C)

IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier 34000, France.

Amel Nasri (A)

IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier 34000, France.

Isabelle Vachier (I)

Department of Respiratory Diseases, CHU Montpellier, Arnaud de Villeneuve Hospital, INSERM, Montpellier 34000, France; MedBioMed, Montpellier, France.

Said Assou (S)

IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier 34000, France.

Arnaud Bourdin (A)

Department of Respiratory Diseases, CHU Montpellier, Arnaud de Villeneuve Hospital, INSERM, Montpellier 34000, France; PhyMedExp INSERM 1046, University of Montpellier, Montpellier, France. Electronic address: a-bourdin@chu-montpellier.fr.

John De Vos (J)

IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier 34000, France; Department of Cell and Tissue Engineering, Saint-Eloi Hospital, Montpellier 34000, France. Electronic address: john.devos@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH